Filippos T Filippidis1, Vasiliki Gerovasili2, Constantine I Vardavas3, Israel T Agaku4, Yannis Tountas5. 1. School of Public Health, Imperial College London, The Reynolds Building, St. Dunstan's Road, London W6 8RP, UK; Center for Health Services Research, University of Athens, Alexandroupoleos 25, 11527, Athens, Greece. Electronic address: f.filippidis@imperial.ac.uk. 2. 1st Critical Care Medicine Department, Cardiopulmonary Exercise Testing and Rehabilitation Laboratory, "Evgenidio" Hospital, NKUA, Papadiamantopoulou 20, 15128, Athens, Greece. Electronic address: gerovasili.v@gmail.com. 3. Center for Global Tobacco Control, Department of Social and Behavioral Sciences, Harvard School of Public Health, 401 Park Drive, 4th West, Boston, MA, 02215 USA. Electronic address: vardavas@hsph.harvard.edu. 4. Center for Global Tobacco Control, Department of Social and Behavioral Sciences, Harvard School of Public Health, 401 Park Drive, 4th West, Boston, MA, 02215 USA. Electronic address: iagaku@post.harvard.edu. 5. Center for Health Services Research, University of Athens, Alexandroupoleos 25, 11527, Athens, Greece. Electronic address: ytountas@med.uoa.gr.
Abstract
OBJECTIVE: To identify determinants of use of smoking cessation aids among current and former smokers in the European Union (EU). METHODS: Data from n=9921 current and ex-smokers from 27 European countries (Eurobarometer 77.1, February-March 2012) were analysed. Multivariate binary logistic regression was used to assess for correlates of use of any recommended aid with proven efficacy, defined as use of pharmacotherapy or psychosocial counselling (p<0.05). The regression analyses assessed for socio-demographic characteristics, EU region, as well as scope of national smoking cessation policies. RESULTS: Among current smokers who had made a quit attempt and ex-smokers, 19.9% had used any recommended aid with proven efficacy. Respondents from Northern (adjusted odds ratio [aOR]=1.90), Western (aOR=3.21) and Eastern Europe (aOR=1.69) were more likely to have used an efficacious smoking cessation aid compared to respondents from Southern Europe (all p<0.05). Respondents in countries with comprehensive tobacco cessation programmes that offered cost-covered national quit lines, medication, and other cessation services had increased likelihood of using efficacious cessation aids (OR=1.29; 95% Confidence Interval: 1.07-1.55). CONCLUSIONS: These findings underscore the need for enhanced and sustained efforts to ensure increased access to cessation services and aids as part of a comprehensive tobacco control programme.
OBJECTIVE: To identify determinants of use of smoking cessation aids among current and former smokers in the European Union (EU). METHODS: Data from n=9921 current and ex-smokers from 27 European countries (Eurobarometer 77.1, February-March 2012) were analysed. Multivariate binary logistic regression was used to assess for correlates of use of any recommended aid with proven efficacy, defined as use of pharmacotherapy or psychosocial counselling (p<0.05). The regression analyses assessed for socio-demographic characteristics, EU region, as well as scope of national smoking cessation policies. RESULTS: Among current smokers who had made a quit attempt and ex-smokers, 19.9% had used any recommended aid with proven efficacy. Respondents from Northern (adjusted odds ratio [aOR]=1.90), Western (aOR=3.21) and Eastern Europe (aOR=1.69) were more likely to have used an efficacious smoking cessation aid compared to respondents from Southern Europe (all p<0.05). Respondents in countries with comprehensive tobacco cessation programmes that offered cost-covered national quit lines, medication, and other cessation services had increased likelihood of using efficacious cessation aids (OR=1.29; 95% Confidence Interval: 1.07-1.55). CONCLUSIONS: These findings underscore the need for enhanced and sustained efforts to ensure increased access to cessation services and aids as part of a comprehensive tobacco control programme.
Authors: Filippos T Filippidis; Anthony A Laverty; Ute Mons; Carlos Jimenez-Ruiz; Constantine I Vardavas Journal: Tob Control Date: 2018-03-21 Impact factor: 7.552
Authors: Karin Hummel; Gera E Nagelhout; Geoffrey T Fong; Constantine I Vardavas; Sophia Papadakis; Aleksandra Herbeć; Ute Mons; Bas van den Putte; Ron Borland; Esteve Fernández; Hein de Vries; Ann McNeill; Shannon Gravely; Krzysztof Przewoźniak; Piroska Kovacs; Antigona C Trofor; Marc C Willemsen Journal: Tob Induc Dis Date: 2018 Impact factor: 2.600
Authors: Eliana Finocchio; Mario Olivieri; Giang Nguyen; Oscar Bortolami; Pierpaolo Marchetti; Roberta Vesentini; Lorena Torroni; Gianluca Spiteri; Francesca Locatelli; Francesca Moretti; Alessandro Fois; Pietro Pirina; Marcello Ferrari; Giuseppe Verlato Journal: Int J Environ Res Public Health Date: 2021-01-21 Impact factor: 3.390
Authors: Filippos T Filippidis; Anthony A Laverty; Vasiliki Gerovasili; Constantine I Vardavas Journal: Tob Control Date: 2016-05-24 Impact factor: 7.552